* Immunic Inc reported a quarterly adjusted loss of 24 cents per share for the quarter ended September 30, higher than the same quarter last year, when the company reported EPS of -51 cents. The mean expectation of six analysts for the quarter was for a loss of 22 cents per share. Wall Street expected results to range from -23 cents to -19 cents per share.
* Reported revenue was zero; analysts expected $7.50 thousand.
* Immunic Inc's reported EPS for the quarter was a loss of 24 cents.
* The company reported a quarterly loss of $24.37 million.
* Immunic Inc shares had fallen by 28.5% this quarter and lost 21.3% so far this year.
FORECAST CHANGES
* The mean earnings estimate of analysts had risen by about 5.3% in the last three months.
* In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.
RECOMMENDATIONS
* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 6 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."
* The average consensus recommendation for the biotechnology & medical research peer group is also "buy"
Wall Street's median 12-month price target for Immunic Inc is 10.25 This summary was machine generated from LSEG data November 7 at 02:40 p.m. UTC. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING ESTIMATE ACTUAL BEAT, MET,
MISSED
Sep. 30 2024 -0.22 -0.24 Missed
Jun. 30 2024 -0.21
Dec. 31 2023 -0.30
Dec. 31 2023 -0.51 -0.48 Beat
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。